Greylock XII’s KALA BIO KALA Stock Holding History

Greylock XII’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-80	Closed	-$1.65M	–	4
2019 Q1	$1.65M	Hold	80	–	–	2.63%	3
2018 Q4	$976K	Hold	80	–	–	1.22%	3
2018 Q3	$1.97M	Buy	+80	New	+$2.44M	1.39%	3

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Greylock XII's KALA Position: Q2 2019 in Review

Greylock XII sold out of KALA BIO (KALA) in Q2 2019, closing a stake of 80 shares — an estimated $1.65M sold.

Greylock XII first reported a position in KALA in Q3 2018 and held it in 3 quarters. The position peaked at $1.97M in Q3 2018. 63 funds tracked by Wall St. Rank hold KALA as of Q2 2019.

Greylock XII reported no remaining KALA BIO position as of Q2 2019 after selling out during the quarter.
Greylock XII sold 80 KALA BIO shares in Q2 2019, an estimated $1.65M.
Greylock XII first reported a position in KALA BIO in Q3 2018 and held it in 3 quarters.
Greylock XII's KALA BIO position peaked at $1.97M in Q3 2018.
63 funds tracked by Wall St. Rank held KALA BIO as of Q2 2019.

Based on Greylock XII's 13F filing for Q2 2019, filed 14 Aug 2019.